@entity463 multiforme is a devastating @entity5 with an exceedingly poor prognosis. @entity1499 ( @entity6822 ) is a @entity1501 analogue that inhibits DNA synthesis by binding to @entity9796 reductase. Biodegradable nanoparticles are emerging as a promising system for drug delivery to specific tissues. The aims of the current study were pharmacological improvement and preclinical evaluation of @entity6822 -loaded lipid-core nanocapsules ( @entity6822 -LNCs) in a @entity463 model. Cell viability was assessed using the @entity98 assay, and the cell cycle was characterized by flow cytometry analysis of @entity2667 staining. Apoptosis was measured using an AnnexinV kit and by examining active @entity4124 immunocontent. In vivo @entity11 implantation was performed in @entity35 , followed by measurement of the @entity5 size and tumoral apoptosis, @entity1976 immunohistochemistry and analyses of toxicological parameters. @entity6822 -LNCs with increased encapsulation efficiency were successfully prepared. Our in vitro results showed a decrease in @entity11 cell viability after @entity6822 -LNC treatment that was preceded by cell cycle arrest, leading the cells to undergo apoptotic death, as indicated by AnnexinV staining and increased active @entity4124 protein levels. In the in vivo @entity11 model, we observed a decrease in the @entity5 size and an increase in apoptosis in the @entity5 microenvironment (based on the AnnexinV assay and @entity1976 measurement). @entity6822 -LNC treatment decreased the leukocyte number but altered neither toxicological tissue marker expression nor metabolic parameters. The present results reveal that @entity6822 -LNCs represented an efficient formulation in a preclinical model of @entity11 and are a potential candidate for clinical trials.

Pharmacological Improvement and Preclinical Evaluation of XXXX -Loaded Lipid-Core Nanocapsules in a @entity463 Model.

@entity1501 :: ('MESH:D005492', 'Chemical') :: ['folic acid'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity2667 :: ('MESH:D011419', 'Chemical') :: ['propidium iodide'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cerebral tumor'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity1976 :: ('24224(Tax:10116)', 'Gene') :: ['BCL-2'] @entity11 :: ('MESH:D005910', 'Disease') :: ['glioma'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity9796 :: ('MESH:C010920', 'Chemical') :: ['dihydrofolate'] @entity4124 :: ('25402(Tax:10116)', 'Gene') :: ['caspase-3'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma', 'Glioblastoma']
@entity1499 :: (MESH:D008727,Chemical) :: ['Methotrexate']
